Fosphenytoin

Fosphenytoin
Clinical data
Trade names	Cerebyx, others
AHFS/Drugs.com	Monograph
MedlinePlus	a604036
License data	US DailyMed: Fosphenytoin;
Routes of; administration	Intravenous, intramuscular
ATC code	N03AB05 (WHO) ;
Legal status
Legal status	CA: ℞-only; US: ℞-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	100% (IM)
Protein binding	95–99%
Metabolism	Liver
Elimination half-life	15 minutes to convert to phenytoin
Excretion	Kidney (as phenytoin)
Identifiers
	IUPAC name (2,5-Dioxo-4,4-diphenyl-imidazolidin-1-yl)methoxyphosphonic acid;
CAS Number	93390-81-9 ;
PubChem CID	56339;
IUPHAR/BPS	7190;
DrugBank	DB01320 ;
ChemSpider	50839 ;
UNII	B4SF212641;
KEGG	D07993 ;
ChEMBL	ChEMBL919 ;
CompTox Dashboard (EPA)	DTXSID9044299 ;
Chemical and physical data
Formula	C16H15N2O6P
Molar mass	362.278 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C3N(C(=O)C(c1ccccc1)(c2ccccc2)N3)COP(=O)(O)O;
	InChI InChI=1S/C16H15N2O6P/c19-14-16(12-7-3-1-4-8-12,13-9-5-2-6-10-13)17-15(20)18(14)11-24-25(21,22)23/h1-10H,11H2,(H,17,20)(H2,21,22,23) ; Key:XWLUWCNOOVRFPX-UHFFFAOYSA-N ;
	(what is this?) (verify)

Fosphenytoin, also known as fosphenytoin sodium, and sold under the brand name Cerebyx among others, is a water-soluble phenytoin prodrug that is administered intravenously to deliver phenytoin, potentially more safely than intravenous phenytoin. It is used in the acute treatment of convulsive status epilepticus.

Fosphenytoin was developed in 1996.^[2]

^ "Cerebyx Product information". Health Canada. 7 October 2022. Retrieved 16 February 2025.
^ Pitkänen A, Schwartzkroin PA, Moshé SL (2005). Models of Seizures and Epilepsy. Burlington: Elsevier. p. 539. ISBN 9780080457024.

[1] "Cerebyx Product information". Health Canada. 7 October 2022. Retrieved 16 February 2025.

[2] Pitkänen A, Schwartzkroin PA, Moshé SL (2005). Models of Seizures and Epilepsy. Burlington: Elsevier. p. 539. ISBN 9780080457024.

[1]

[2]